MedPath

ASTELLAS PHARMA

🇯🇵Japan
Ownership
-
Established
2005-01-01
Employees
-
Market Cap
$22.5B
Website
https://www.astellas.com/

A Study of Oral Dosing of ASP0456 in Patients With Chronic Constipation

Phase 3
Completed
Conditions
Chronic Constipation
Interventions
Drug: Placebo
First Posted Date
2016-06-22
Last Posted Date
2024-10-18
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
186
Registration Number
NCT02809105
Locations
🇯🇵

Site JP00029, Aichi, Japan

🇯🇵

Site JP00030, Aichi, Japan

🇯🇵

Site JP00021, Chiba, Japan

and more 36 locations

A Food Effect Study to Evaluate the Pharmacokinetics of ASP1517

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
First Posted Date
2016-06-20
Last Posted Date
2016-08-24
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
16
Registration Number
NCT02805374
Locations
🇯🇵

Site JP00001, Tokyo, Japan

Post-marketing Surveillance of Bixalomer in Patients With Pre-dialysis Chronic Kidney Disease

Completed
Conditions
Chronic Kidney Disease
Interventions
First Posted Date
2016-06-20
Last Posted Date
2024-10-16
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
144
Registration Number
NCT02805348
Locations
🇯🇵

Site JP00006, Aichi, Japan

🇯🇵

Site JP00010, Ehime, Japan

🇯🇵

Site JP00012, Fukuoka, Japan

and more 11 locations

Study to Evaluate the Safety and Pharmacokinetics of ASP2151 in Healthy Non-elderly and Elderly Subjects

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Drug: Placebo
First Posted Date
2016-06-10
Last Posted Date
2016-08-29
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
36
Registration Number
NCT02796118
Locations
🇯🇵

Site JP00001, Osaka, Japan

Efficacy and Safety of Dorner Tablets and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients

Phase 4
Terminated
Conditions
Type 2 Diabetes Mellitus
Interventions
First Posted Date
2016-06-01
Last Posted Date
2016-06-21
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
190
Registration Number
NCT02786979
Locations
🇨🇳

Site CN00001, Beijing, Beijing, China

🇨🇳

Site CN00002, Beijing, Beijing, China

🇨🇳

Site CN00004, Guangzhou, Guangdong, China

and more 3 locations

A Study of Intermittent Oral Dosing of ASP1517 in Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia

Phase 3
Completed
Conditions
Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia
Interventions
First Posted Date
2016-05-23
Last Posted Date
2024-10-30
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
56
Registration Number
NCT02780726
Locations
🇯🇵

Site JP00002, Aichi, Japan

🇯🇵

Site JP00004, Aichi, Japan

🇯🇵

Site JP00010, Aichi, Japan

and more 12 locations

A Study of Intermittent Oral Dosing of ASP1517 in Erythropoieses Stimulating Agent (ESA)-Naive Hemodialysis Chronic Kidney Disease Patients With Anemia

Phase 3
Completed
Conditions
ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia
Interventions
First Posted Date
2016-05-23
Last Posted Date
2024-10-30
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
75
Registration Number
NCT02780141
Locations
🇯🇵

Site JP00003, Aichi, Japan

🇯🇵

Site JP00005, Aichi, Japan

🇯🇵

Site JP00042, Aichi, Japan

and more 44 locations

A Long Term Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia Converted From Erythropoieses Stimulating Agent (ESA) Treatment

Phase 3
Completed
Conditions
Hemodialysis Patients With Renal Anemia
Interventions
First Posted Date
2016-05-20
Last Posted Date
2024-10-31
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
164
Registration Number
NCT02779764
Locations
🇯🇵

Site JP00017, Aichi, Japan

🇯🇵

Site JP00005, Fukuoka, Japan

🇯🇵

Site JP00004, Gunma, Japan

and more 22 locations

A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Metformin

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
First Posted Date
2016-05-03
Last Posted Date
2024-10-16
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
24
Registration Number
NCT02760342
Locations
🇯🇵

Site JP00001, Kagoshima, Japan

Dose Range-finding Study of ASP1585 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia

Phase 2
Completed
Conditions
Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia
Interventions
First Posted Date
2016-04-28
Last Posted Date
2016-06-21
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
73
Registration Number
NCT02753894
Locations
🇯🇵

Site JP00011, Aichi, Japan

🇯🇵

Site JP00009, Chiba, Japan

🇯🇵

Site JP00010, Chiba, Japan

and more 8 locations
© Copyright 2025. All Rights Reserved by MedPath